Plasma levels of cytokines and chemokines and the risk of mortality in HIV-infected individuals: A case-control analysis nested in a large clinical trial

AIDS

Volumn 29, Issue 7, 2015, Pages 847-851

  French, Martyn A ^a,b   Cozzi Lepri, Alessandro ^c   Arduino, Roberto C ^d   Johnson, Margaret ^e   Achhra, Amit C ^f   Landay, Alan ^g  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

chemokines; CXCL8; cytokines; HIV; interleukin 6; mortality

Indexed keywords

CHEMOKINE; CYTOKINE; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER;

ARTICLE; BLOOD SAMPLING; CASE CONTROL STUDY; CAUSE OF DEATH; CELL ACTIVATION; CELL MIGRATION; CELL PROLIFERATION; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOREACTIVITY; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; BLOOD; CLINICAL TRIAL (TOPIC); FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PATHOLOGY; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS;

BIOMARKERS; CASE-CONTROL STUDIES; CLINICAL TRIALS AS TOPIC; CYTOKINES; FEMALE; HIV INFECTIONS; HUMANS; MALE; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 84928556516     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000618     Document Type: Article

References (23)

1. Hsu DC, Sereti I, Ananworanich J. Serious Non-AIDS events: immunopathogenesis and interventional strategies. AIDS Res Ther 2013; 10:29.
2. Hearps AC, Martin GE, Rajasuriar R, Crowe SM. Inflammatory co-morbidities in HIVR individuals: learning lessons from healthy ageing. Curr HIV/AIDS Rep 2014; 11:20-34.
3. Bastidas S, Graw F, Smith MZ, Kuster H, Gunthard HF, Oxenius A. CD8R T cells are activated in an antigen-independent manner in HIV-infected individuals. J Immunol 2014; 192: 1732-1744.
4. Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, et al. Soluble markers of inflammation and coagulation, but not T-cell activation, are predictors of non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis 2014; 210:1248-1259.
5. Wilson EM, Singh A, Hullsiek KH, Gibson D, Henry WK, Lichtenstein K, et al. Monocyte activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection. J Infect Dis 2014; 210:1396-1406.
6. Hearps AC, Maisa A, Cheng WJ, Angelovich TA, Lichtfuss GF, Palmer CS, et al. HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy. AIDS 2012; 26:843-853.
7. Burdo TH, Lo J, Abbara S, Wei J, DeLelys ME, Preffer F, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 2011; 204:1227-1236.
8. Burdo TH, Weiffenbach A, Woods SP, Letendre S, Ellis RJ, Williams KC. Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. AIDS 2013; 27:1387-1395.
9. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203:780-790.
10. Funderburg NT, Zidar DA, Shive C, Lioi A, Mudd J, Musselwhite LW, et al. Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. Blood 2012; 120:4599-4608.
11. Funderburg NT, Mayne E, Sieg SF, Asaad R, Jiang W, Kalinowska M, et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood 2010; 115:161-167.
12. Cozzi-Lepri A, French MA, Baxter J, Okhuysen P, Plana M, Neuhaus J, et al. Resumption of HIV replication is associated with monocyte/macrophage derived cytokine and chemokine changes: results from a large international clinical trial. AIDS 2011; 25:1207-1217.
13. Duprez DA, Neuhaus J, Kuller LH, Tracy R, Belloso W, De Wit S, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 2012; 7:e44454.
14. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
15. Fuster D, Cheng DM, Quinn EK, Armah KA, Saitz R, Freiberg MS, et al. Inflammatory cytokines and mortality in a cohort of HIV-infected adults with alcohol problems. AIDS 2014; 28: 1059-1064.
16. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, et al. CD4R count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
17. O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics 1984; 40:1079-1087.
18. Papadopoulou C, Corrigall V, Taylor PR, Poston RN. The role of the chemokines MCP-1, GRO-alpha, IL-8 and their receptors in the adhesion of monocytic cells to human atherosclerotic plaques. Cytokine 2008; 43:181-186.
19. Zernecke A, Weber C. Chemokines in atherosclerosis: proceedings resumed. Arterioscler Thromb Vasc Biol 2014; 34:742-750.
20. Ortego M, Bustos C, Hernandez-Presa MA, Tunon J, Diaz C, Hernandez G, et al. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999; 147:253-261.
21. Romano M, Diomede L, Sironi M, Massimiliano L, Sottocorno M, Polentarutti N, et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 2000; 80:1095-1100.
22. Breland UM, Halvorsen B, Hol J, Oie E, Paulsson-Berne G, Yndestad A, et al. A potential role of the CXC chemokine GROalpha in atherosclerosis and plaque destabilization: downregulatory effects of statins. Arterioscler Thromb Vasc Biol 2008; 28:1005-1011.
23. Pereira MM, Santos TP, Aras R, Couto RD, Atta ML, Atta AM. Serum levels of cytokines and chemokines associated with cardiovascular disease in Brazilian patients treated with statins for dyslipidemia. Int Immunopharmacol 2014; 18:66-70.